Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Moderna's Stock Just Tumbled 12%. Here's Why It's Still a Buy.
Moderna's Stock Just Tumbled 12%. Here's Why It's Still a Buy.
Moderna's Stock Just Tumbled 12%. Here's Why It's Still a Buy.
Submitted by
admin
on November 9, 2023 - 9:40am
Source:
Motley Fool
News Tags:
Moderna Therapeutics
vaccines
COVID-19
Headline:
Moderna's Stock Just Tumbled 12%. Here's Why It's Still a Buy.
snippet:
Moderna's stock hasn't done well lately now that coronavirus vaccine sales are falling.
But the biotech has an ambitious plan to launch over a dozen medicines relatively soon.
After dropping sharply, the stock's valuation looks especially favorable at the moment.
Do Not Allow Advertisers to Use My Personal information
